These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3340080)

  • 1. Guanyl nucleotide interactions with dopaminergic binding sites labeled by [3H]spiroperidol in human caudate and putamen: guanyl nucleotides enhance ascorbate-induced lipid peroxidation and cause an apparent loss of high affinity binding sites.
    Andorn AC; Bacon BR; Nguyen-Hunh AT; Parlato SJ; Stitts JA
    Mol Pharmacol; 1988 Feb; 33(2):155-62. PubMed ID: 3340080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat treatment mimics guanosine-5'-triphosphate effects on dopaminergic 3H-ligand binding to bovine caudate membranes.
    Hamblin MW; Creese I
    Mol Pharmacol; 1982 Jan; 21(1):52-6. PubMed ID: 7132962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist high- and low-affinity states of the D2-dopamine receptor in calf brain. Partial conversion by guanine nucleotide.
    Wreggett KA; Seeman P
    Mol Pharmacol; 1984 Jan; 25(1):10-7. PubMed ID: 6231467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
    Zahniser NR; Molinoff PB
    Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
    Leff SE; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes.
    Hamblin MW; Creese I
    Mol Pharmacol; 1982 Jan; 21(1):44-51. PubMed ID: 6127621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computer imaging and analysis of dopamine (D2) and serotonin (S2) binding sites in rat basal ganglia or neocortex labeled by [3H]spiroperidol.
    Altar CA; Kim H; Marshall JF
    J Pharmacol Exp Ther; 1985 May; 233(2):527-38. PubMed ID: 3889277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of dopamine agonist and antagonist binding sites in mammalian retina.
    Makman MH; Dvorkin B; Horowitz SG; Thal LJ
    Brain Res; 1980 Aug; 194(2):403-18. PubMed ID: 6770965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascorbate-induced lipid peroxidation and inhibition of [3H]spiroperidol binding in neostriatal membrane preparations.
    Heikkila RE; Cabbat FS
    J Neurochem; 1983 Nov; 41(5):1384-92. PubMed ID: 6619873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of binding sites for 3H-spiroperidol in human retina.
    McGonigle P; Wax MB; Molinoff PB
    Invest Ophthalmol Vis Sci; 1988 May; 29(5):687-94. PubMed ID: 2452802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic phencyclidine or d-amphetamine treatment on [3H]spiroperidol binding in rat caudate-putamen and nucleus accumbens.
    Daiguji M; Meltzer HY
    Eur J Pharmacol; 1982 Dec; 85(3-4):339-42. PubMed ID: 7151875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [3H]N-propylapomorphine and [3H]spiperone binding in brain indicate two states of the D2-dopamine receptor.
    Battaglia G; Titeler M
    Eur J Pharmacol; 1982 Jul; 81(3):493-8. PubMed ID: 6126376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bromocriptine on 3H-spiroperidol binding sites in rat striatum. Evidence for actions of dopamine receptors not linked to adenylate cyclase.
    Schwarcz R; Fuxe K; Agnati LF; Gustafsson JA
    Life Sci; 1978 Aug; 23(5):465-9. PubMed ID: 692269
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine D-2 receptors in rat caudate-putamen: the lateral to medial gradient does not correspond to dopaminergic innervation.
    Joyce JN; Loeschen SK; Marshall JF
    Brain Res; 1985 Jul; 338(2):209-18. PubMed ID: 3161583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptor binding in bovine intermediate lobe pituitary membranes.
    Sibley DR; Creese I
    Endocrinology; 1980 Nov; 107(5):1405-9. PubMed ID: 7428676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of radioligand oxidation and ascorbate-induced lipid peroxidation on serotonin-1 receptor assay: use of ascorbate and ethylenediamine tetraacetic acid buffers to prevent (3H)-5-HT binding artifacts.
    May PC; Morgan DG; Salo D; Goss JR; Finch CE
    J Neurosci Res; 1988; 20(2):257-62. PubMed ID: 3139891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptors in rat brain regions. Optimal conditions for 3H-agonist binding, pH dependency and lack of inhibition by ascorbic acid.
    Bacopoulos NG
    Biochem Pharmacol; 1982 Oct; 31(19):3085-91. PubMed ID: 7150335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.